Rho kinase polymorphism influences blood pressure and systemic vascular resistance in human twins: Role of heredity

Hypertension

Volumn 47, Issue 5, 2006, Pages 937-947

  Seasholtz, Tammy M ^b   Wessel, Jennifer ^b   Rao, Fangwen ^b   Rana, Brinda K ^b   Khandrika, Srikrishna ^b   Kennedy, Brian P ^b   Lillie, Elizabeth O ^b   Ziegler, Michael G ^b   Smith, Douglas W ^a   Schork, Nicholas J ^b,c,d   Brown, Joan Heller ^b,f   O'Connor, Daniel T ^b,d,e,f  

^a San Diego   (United States)

^b Department of Medicine ^*  (United States)

^c Polymorphism Research Laboratory   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Blood pressure; Hypertension, renal; Renin; Vascular resistance

Indexed keywords

RHO FACTOR; RHO KINASE; VASOACTIVE AGENT; ALDOSTERONE; ASPARAGINE; PROTEIN SERINE THREONINE KINASE; RENIN; RHO-ASSOCIATED KINASE; SIGNAL PEPTIDE; THREONINE;

ADOLESCENT; ADULT; AGED; ARTERY COMPLIANCE; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DNA POLYMORPHISM; FEMALE; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HEART OUTPUT; HEART RATE; HEREDITY; HERITABILITY; HOMOZYGOTE; HORMONE RELEASE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; MALE; MONOZYGOTIC TWINS; PLEIOTROPY; PRESSORECEPTOR; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STRESS; SYSTOLIC BLOOD PRESSURE; TWINS; VASCULAR RESISTANCE; BLOOD; BLOOD PRESSURE; COLD; GENETIC POLYMORPHISM; GENETICS; PATHOPHYSIOLOGY; PHENOTYPE; PHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALDOSTERONE; ASPARAGINE; BLOOD PRESSURE; CARDIAC OUTPUT; COLD; FEMALE; GENOTYPE; HOMOZYGOTE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PHENOTYPE; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PRESSORECEPTORS; PROTEIN-SERINE-THREONINE KINASES; RENIN; STRESS; THREONINE; VASCULAR RESISTANCE;

EID: 33646164662     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000217364.45622.f0     Document Type: Article

References (60)

1. Ridley AJ, Hall A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell. 1992;70:389-399.
2. Paterson HF, Self AJ, Garrett MD, Just I, Aktories K, Hall A. Microinjection of recombinant p21rho induces rapid changes in cell morphology. J Cell Biol. 1990;111:1001-1007.
3. Jalink K, van Corven EJ, Hengeveld T, Morii N, Narumiya S, Moolenaar WH. Inhibition of lysophosphatidate- and thrombin-induced neurite retraction and neuronal cell rounding by ADP ribosylation of the small GTP-binding protein Rho. J Cell Biol. 1994;126:801-810.
4. Majumdar M, Seasholtz TM, Goldstein D, de Lanerolle P, Brown JH. Requirement for Rho-mediated myosin light chain phosphorylation in thrombin-stimulated cell rounding and its dissociation from mitogenesis. J Biol Chem. 1998;273:10099-10106.
5. Offermanns S, Laugwitz KL, Spicher K, Schultz G. G proteins of the G12 family are activated via thromboxane A2 and thrombin receptors in human platelets. Proc Natl Acad Sci U S A. 1994;91:504-508.
6. Barr AJ, Brass LF, Manning DR. Reconstitution of receptors and GTP-binding regulatory proteins (G proteins) in Sf9 cells. A direct evaluation of selectivity in receptor.G protein coupling. J Biol Chem. 1997;272:2223-2229.
7. Noda M, Yasuda-Fukazawa C, Moriishi K, Kato T, Okuda T, Kurokawa K, Takuwa Y. Involvement of rho in GTP γ S-induced enhancement of phosphorylation of 20 kDa myosin light chain in vascular smooth muscle cells: inhibition of phosphatase activity. FEBS Lett. 1995;367:246-250.
8. Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, Yamamori B, Feng J, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science. 1996;273:245-248.
9. Kureishi Y, Kobayashi S, Amano M, Kimura K, Kanaide H, Nakano T, Kaibuchi K, Ito M. Rho-associated kinase directly induces smooth muscle contraction through myosin light chain phosphorylation. J Biol Chem. 1997;272:12257-12260.
10. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389:990-994.
11. Seasholtz TM, Majumdar M, Kaplan DD, Brown JH. Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ Res. 1999;84:1186-1193.
12. Seasholtz TM, Zhang T, Morissette MR, Howes AL, Yang AH, Brown JH. Increased expression and activity of RhoA are associated with increased DNA synthesis and reduced p27(Kip1) expression in the vasculature of hypertensive rats. Circ Res. 2001;89:488-495.
13. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol. 2003;4:446-456.
14. Seasholtz TM, Brown JH. RHO signaling in vascular diseases. Mol Interv. 2004;4:348-357.
15. Lee DL, Webb RC, Jin L. Hypertension and RhoA/Rho-kinase signaling in the vasculature: highlights from the recent literature. Hypertension. 2004;44:796-799.
16. Chrissobolis S, Sobey CG. Evidence that Rho-kinase activity contributes to cerebral vascular tone in vivo and is enhanced during chronic hypertension: comparison with protein kinase C. Circ Res. 2001;88:774-779.
17. Jarajapu YP, Knot HJ. Relative contribution of Rho kinase and protein kinase C to myogenic tone in rat cerebral arteries in hypertension. Am J Physiol Heart Circ Physiol. 2005;289:H1917-H1922.
18. Mukai Y, Shimokawa H, Matoba T, Kandabashi T, Satoh S, Hiroki J, Kaibuchi K, Takeshita A. Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J. 2001;15:1062-1064.
19. Buetow KH, Edmonson M, MacDonald R, Clifford R, Yip P, Kelley J, Little DP, Strausberg R, Koester H, Cantor CR, Braun A. High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc Natl Acad Sci U S A. 2001;98:581-584.
20. Le Corre P, Parmer RJ, Kailasam MT, Kennedy BP, Skaar TP, Ho H, Leverge R, Smith DW, Ziegler MG, Insel PA, Schork NJ, Flockhart DA, O'Connor DT. Human sympathetic activation by α2-adrenergic blockade with yohimbine: bimodal, epistatic influence of cytochrome P450-mediated drug metabolism. Clin Pharmacol Ther. 2004;76:139-153.
21. Cockburn M, Hamilton A, Zadnick J, Cozen W, Mack TM. The occurrence of chronic disease and other conditions in a large population-based cohort of native Californian twins. Twin Res. 2002;5:460-467.
22. Zhang L, Rao F, Wessel J, Kennedy BP, Rana BK, Taupenot L, Lillie EO, Cockburn M, Schork NJ, Ziegler MG, O'Connor DT. Functional allelic heterogeneity and pleiotropy of a repeat polymorphism in tyrosine hydroxylase: prediction of catecholamines and response to stress in twins. Physiol Genomics. 2004;19:277-291.
23. O'Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ. Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens. 2002;20:1335-1345.
24. O'Connor DT, Insel PA, Ziegler MG, Hook VY, Smith DW, Hamilton BA, Taylor PW, Parmer RJ. Heredity and the autonomic nervous system in human hypertension. Curr Hypertens Rep. 2000;2:16-22.
25. Herrmann V, Buscher R, Go MM, Ring KM, Hofer JK, Kailasam MT, O'Connor DT, Parmer RJ, Insel PA. β2-adrenergic receptor polymorphisms at codon 16, cardiovascular phenotypes and essential hypertension in whites and African Americans. Am J Hypertens. 2000;13:1021-1026.
26. Kennedy B, Ziegler MG. A more sensitive and specific radioenzymatic assay for catecholamines. Life Sci. 1990;47:2143-2153.
27. Parmer RJ, Cervenka JH, Stone RA, O'Connor DT. Autonomic function in hypertension. Are there racial differences? Circulation. 1990;81:1305-1311.
28. Brinton TJ, Cotter B, Kailasam MT, Brown DL, Chio SS, O'Connor DT, DeMaria AN. Development and validation of a noninvasive method to determine arterial pressure and vascular compliance. Am J Cardiol. 1997;80:323-330.
29. Brinton TJ, Kailasam MT, Wu RA, Cervenka JH, Chio SS, Parmer RJ, DeMaria AN, O'Connor DT. Arterial compliance by cuff sphygmomanometer. Application to hypertension and early changes in subjects at genetic risk. Hypertension. 1996;28:599-603.
30. Do KA, Broom BM, Kuhnert P, Duffy DL, Todorov AA, Treloar SA, Martin NG. Genetic analysis of the age at menopause by using estimating equations and Bayesian random effects models. Stat Med. 2000;19:1217-1235.
31. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet. 1998;62:1198-1211.
32. Halperin E, Eskin E. Haplotype reconstruction from genotype data using Imperfect Phylogeny. Bioinformatics. 2004;20:1842-1849.
33. Ito K, Hirooka Y, Kishi T, Kimura Y, Kaibuchi K, Shimokawa H, Takeshita A. Rho/Rho-kinase pathway in the brainstem contributes to hypertension caused by chronic nitric oxide synthase inhibition. Hypertension. 2004;43:156-162.
34. Ito K, Hirooka Y, Sagara Y, Kimura Y, Kaibuchi K, Shimokawa H, Takeshita A, Sunagawa K. Inhibition of Rho-kinase in the brainstem augments baroreflex control of heart rate in rats. Hypertension. 2004;44:478-483.
35. Kokubu N, Satoh M, Takayanagi I. Involvement of botulinum C3-sensitive GTP-binding proteins in α 1-adrenoceptor subtypes mediating Ca(2+)-sensitization. Eur J Pharmacol. 1995;290:19-27.
36. Hirata K, Kikuchi A, Sasaki T, Kuroda S, Kaibuchi K, Matsuura Y, Seki H, Saida K, Takai Y. Involvement of rho p21 in the GTP-enhanced calcium ion sensitivity of smooth muscle contraction. J Biol Chem. 1992;267:8719-8722.
37. Seko T, Ito M, Kureishi Y, Okamoto R, Moriki N, Onishi K, Isaka N, Hartshorne DJ, Nakano T. Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circ Res. 2003;92:411-418.
38. Moriki N, Ito M, Seko T, Kureishi Y, Okamoto R, Nakakuki T, Kongo M, Isaka N, Kaibuchi K, Nakano T. RhoA activation in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Hypertens Res. 2004;27:263-270.
39. Weber DS, Webb RC. Enhanced relaxation to the rho-kinase inhibitor Y-27632 in mesenteric arteries from mineralocorticoid hypertensive rats. Pharmacology. 2001;63:129-133.
40. Asano M, Nomura Y. Comparison of inhibitory effects of Y-27632, a Rho kinase inhibitor, in strips of small and large mesenteric arteries from spontaneously hypertensive and normotensive Wistar-Kyoto rats. Hypertens Res. 2003;26:97-106.
41. Sauzeau V, Le Mellionnec E, Bertoglio J, Scalbert E, Pacaud P, Loirand G. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res. 2001;88:1102-1104.
42. Laufs U, Marra D, Node K, Liao JK. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem. 1999;274:21926-21931.
43. Sawada N, Itoh H, Ueyama K, Yamashita J, Doi K, Chun TH, Inoue M, Masatsugu K, Saito T, Fukunaga Y, Sakaguchi S, Arai H, Ohno N, Komeda M, Nakao K. Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation. 2000;101:2030-2033.
44. Negoro N, Hoshiga M, Seto M, Kohbayashi E, Ii M, Fukui R, Shibata N, Nakakoji T, Nishiguchi F, Sasaki Y, Ishihara T, Ohsawa N. The kinase inhibitor fasudil (HA-1077) reduces intimal hyperplasia through inhibiting migration and enhancing cell loss of vascular smooth muscle cells. Biochem Biophys Res Commun. 1999;262:211-215.
45. Mallat Z, Gojova A, Sauzeau V, Brun V, Silvestre JS, Esposito B, Merval R, Groux H, Loirand G, Tedgui A. Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice. Circ Res. 2003;93:884-888.
46. Maesaki R, Ihara K, Shimizu T, Kuroda S, Kaibuchi K, Hakoshima T. The structural basis of Rho effector recognition revealed by the crystal structure of human RhoA complexed with the effector domain of PKN/PRK1. Mol Cell. 1999;4:793-803.
47. Lei M, Lu W, Meng W, Parrini MC, Eck MJ, Mayer BJ, Harrison SC. Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch. Cell. 2000;102:387-397.
48. Shimizu T, Ihara K, Maesaki R, Amano M, Kaibuchi K, Hakoshima T. Parallel coiled-coil association of the RhoA-binding domain in Rhokinase. J Biol Chem. 2003;278:46046-46051.
49. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet. 2001;358:1682-1686.
50. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., Jones DW, Materson BJ, Oparil S, Wright JT, Jr, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
51. Liszka HA, Mainous AG, 3rd, King DE, Everett CJ, Egan BM. Prehypertension and cardiovascular morbidity. Ann Fam Med. 2005;3:294-299.
52. Schwartz AR, Gerin W, Davidson KW, Pickering TG, Brosschot JF, Thayer JF, Christenfeld N, Linden W. Toward a causal model of cardiovascular responses to stress and the development of cardiovascular disease. Psychosom Med. 2003;65:22-35.
53. Snieder H, Harshfield GA, Barbeau P, Pollock DM, Pollock JS, Treiber FA. Dissecting the genetic architecture of the cardiovascular and renal stress response. Biol Psychol. 2002;61:73-95.
54. Treiber FA, Kamarck T, Schneiderman N, Sheffield D, Kapuku G, Taylor T. Cardiovascular reactivity and development of preclinical and clinical disease states. Psychosom Med. 2003;65:46-62.
55. Boomsma D, Busjahn A, Peltonen L. Classical twin studies and beyond. Nat Rev Genet. 2002;3:872-882.
56. Kupper N, Willemsen G, Riese H, Posthuma D, Boomsma DI, de Geus EJ. Heritability of daytime ambulatory blood pressure in an extended twin design. Hypertension. 2005;45:80-85.
57. Vinck WJ, Fagard RH, Loos R, Vlietinck R. The impact of genetic and environmental influences on blood pressure variance across age-groups. J Hypertens. 2001;19:1007-1013.
58. Hottenga JJ, Boomsma DI, Kupper N, Posthuma D, Snieder H, Willemsen G, de Geus EJ. Heritability and stability of resting blood pressure. Twin Res Hum Genet. 2005;8:499-508.
59. Knowler WC, Williams RC, Pettitt DJ, Steinberg AG. Gm3;5,13,14 and type 2 diabetes mellitus: an association in Am Indians with genetic admixture. Am J Hum Genet. 1988;43:520-526.
60. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D. The structure of haplotype blocks in the human genome. Science. 2002;296:2225-2229.